All In Biotech

Drug Trial Radar · NCT07734649

Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older

A Phase 1/2, Randomized, Controlled, Observer-Blind Study in Adults 60 Years of Age and Older to Evaluate the Immunogenicity and Safety of Different Dose Levels of a Bivalent Vaccine Candidate Against Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV)

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 2,400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,400

Planned (sponsor's estimate)

Start

Jul 22, 2026

Primary completion

May 3, 2028

Study completion May 3, 2028

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jul 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a Phase 1/2, randomized, observer-blind, active and placebo-controlled, multi-center study to be conducted in approximately 2400 adults 60 years of age and older. The aim of the study is to evaluate the immunogenicity and safety of an RSV+HMPV vaccine candidate for the prevention of RSV and HMPV disease among adults 60 years of age and older. While there are 3 FDA approved/licensed RSV vaccines currently available to the public, no vaccine is available for the prevention of HMPV in older adults. This study is intended to provide data in support of further clinical development of the RSV+HMPV vaccine candidate. The study will consist of 4 cohorts and 11 vaccine groups (RSV+HMPV \[6 dose levels\], placebo and 4 control groups). The duration of the study will be approximately 12 months for each participant.

Conditions

  • Respiratory Syncytial Virus Immunization
  • Human Metapneumovirus Immunization
  • Healthy Volunteers

Interventions

  • RSV+HMPV vaccineBiological

    RSV + HMPV Candidate Vaccine

  • Control Vaccine 3Biological

    Control Vaccine 3

  • Control Vaccine 4Biological

    Control Vaccine 4

  • Control Vaccine 2Biological

    Control Vaccine 2

  • PlaceboOther

    Placebo

  • Control Vaccine 1Biological

    Control Vaccine 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RSV A serum nAb (neutralizing antibodies) titersTime frame: At Day 1 and Day 29
  2. RSV B serum nAb titersTime frame: At Day 1 and Day 29
  3. HMPV A serum nAb titersTime frame: At Day 1 and Day 29
  4. HMPV B serum nAb titersTime frame: At Day 1 and Day 29
  5. Unsolicited systemic Adverse Events (AEs) that occur within 30 minutes after vaccinationTime frame: Within 30 minutes after vaccination
  6. Presence of solicited injection site and systemic reactionsTime frame: For 8 days, including the day of vaccination
  7. Presence of Unsolicited AEsTime frame: For 28 days, including day of vaccination
  8. Presence of medically attended AEs (MAAEs)Time frame: Within 6 months after vaccination
  9. Presence of Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)Time frame: Throughout the study (approximately 12 months)
  10. Presence of out-of-range biological test resultsTime frame: At Day 09

Locations

50 sites in 1 country. Site status is shown where the registry gives one.

  • Hawthorne Health - Gadsden- Site Number : 8400025

    Gadsden, Alabama · Recruiting

  • Accel Research Sites Network - Birmingham- Site Number : 8400065

    Vestavia Hills, Alabama · Recruiting

  • Marvel Clinical Research- Site Number : 8400006

    Huntington Beach, California · Recruiting

  • Velocity Clinical Research - San Diego- Site Number : 8400019

    La Mesa, California · Recruiting

  • Long Beach Research Institute- Site Number : 8400005

    Long Beach, California · Recruiting

  • Acclaim Clinical Research- Site Number : 8400033

    San Diego, California · Recruiting

  • Velocity Clinical Research - Washington DC- Site Number : 8400021

    Washington D.C., District of Columbia · Recruiting

  • Accel Research Sites Network - DeLand Clinical Research Unit- Site Number : 8400064

    DeLand, Florida · Recruiting

  • Velocity Clinical Research - New Smyrna Beach- Site Number : 8400017

    Edgewater, Florida · Recruiting

  • Accel Research Sites - Lakeland Clinical Research Unit- Site Number : 8400073

    Lakeland, Florida · Recruiting

  • Accel Research Sites - St. Petersburg - Largo- Site Number : 8400067

    Largo, Florida · Recruiting

  • Accel Research Sites - Maitland Clinical Research Unit- Site Number : 8400074

    Maitland, Florida · Recruiting

  • Alcanza - Innovation Medical Research Center - Palmetto- Site Number : 8400069

    Palmetto Bay, Florida · Recruiting

  • Accel Research Sites - NeuroStudies- Site Number : 8400063

    Decatur, Georgia · Recruiting

  • North Georgia Clinical Research- Site Number : 8400078

    Woodstock, Georgia · Recruiting

  • DM Clinical Research - Chicago- Site Number : 8400050

    Melrose Park, Illinois · Recruiting

  • Enspire Clinical Research- Site Number : 8400077

    Peoria, Illinois · Recruiting

  • DM Clinical Research - Indianapolis- Site Number : 8400082

    Indianapolis, Indiana · Recruiting

  • Velocity Clinical Research - New Orleans- Site Number : 8400022

    New Orleans, Louisiana · Recruiting

  • Boston Clinical Trials- Site Number : 8400070

    Boston, Massachusetts · Recruiting

  • DM Clinical Research - Brookline- Site Number : 8400055

    Brookline, Massachusetts · Recruiting

  • ActivMed Practices & Research - Methuen- Site Number : 8400066

    Methuen, Massachusetts · Recruiting

  • QUEST Research Institute- Site Number : 8400068

    Farmington Hills, Michigan · Recruiting

  • DM Clinical Research - Detroit- Site Number : 8400049

    Southfield, Michigan · Recruiting

  • Velocity Clinical Research - Lincoln - Valley Road- Site Number : 8400016

    Lincoln, Nebraska · Recruiting

  • Velocity Clinical Research - Omaha- Site Number : 8400012

    Omaha, Nebraska · Recruiting

  • Alliance Clinical - Las Vegas- Site Number : 8400034

    Las Vegas, Nevada · Recruiting

  • DM Clinical Research - New Jersey- Site Number : 8400044

    Jersey City, New Jersey · Recruiting

  • Hawthorne - Bienstar Lindenwold- Site Number : 8400027

    Lindenwold, New Jersey · Recruiting

  • DM Clinical Research - Albuquerque- Site Number : 8400051

    Albuquerque, New Mexico · Recruiting

  • Hawthorne Health - Staten Island- Site Number : 8400026

    Staten Island, New York · Recruiting

  • Velocity Clinical Research - Cleveland- Site Number : 8400024

    Beachwood, Ohio · Recruiting

  • Velocity Clinical Research - Springdale- Site Number : 8400014

    Cincinnati, Ohio · Recruiting

  • DM Clinical Research - Philadelphia- Site Number : 8400046

    Philadelphia, Pennsylvania · Recruiting

  • Velocity Clinical Research - Providence- Site Number : 8400018

    East Greenwich, Rhode Island · Recruiting

  • Coastal Carolina Research Center - North Charleston- Site Number : 8400061

    North Charleston, South Carolina · Recruiting

  • Velocity Clinical Research - Austin- Site Number : 8400013

    Austin, Texas · Recruiting

  • Zenos Clinical Research- Site Number : 8400032

    Dallas, Texas · Recruiting

  • DM Clinical Research - CyFair Clinical Research Center- Site Number : 8400058

    Houston, Texas · Recruiting

  • Texas Center for Drug Development - Houston- Site Number : 8400043

    Houston, Texas · Recruiting

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.